Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating t… Read more
Market Cap & Net Worth: Alar Pharmaceuticals Inc. (6785)
Alar Pharmaceuticals Inc. (TWO:6785) has a market capitalization of $367.45 Million (NT$12.16 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #14834 globally and #525 in its home market, demonstrating a -0.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alar Pharmaceuticals Inc.'s stock price NT$182.00 by its total outstanding shares 66800000 (66.80 Million).
Alar Pharmaceuticals Inc. Market Cap History: 2020 to 2026
Alar Pharmaceuticals Inc.'s market capitalization history from 2020 to 2026. Data shows growth from $98.39 Million to $367.45 Million (29.30% CAGR).
Alar Pharmaceuticals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alar Pharmaceuticals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.88x
Alar Pharmaceuticals Inc.'s market cap is 0.88 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.08x
Alar Pharmaceuticals Inc.'s market cap is 1.08 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $98.39 Million | $600.00K | -$142.80 Million | 163.98x | N/A |
| 2022 | $229.90 Million | $800.00K | -$19.87 Million | 287.38x | N/A |
| 2023 | $411.62 Million | $469.27 Million | $382.62 Million | 0.88x | 1.08x |
Competitor Companies of 6785 by Market Capitalization
Companies near Alar Pharmaceuticals Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Alar Pharmaceuticals Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Alar Pharmaceuticals Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Alar Pharmaceuticals Inc.'s market cap moved from $98.39 Million to $ 367.45 Million, with a yearly change of 29.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$367.45 Million | -40.13% |
| 2025 | NT$613.77 Million | +114.84% |
| 2024 | NT$285.68 Million | -30.59% |
| 2023 | NT$411.62 Million | +79.04% |
| 2022 | NT$229.90 Million | +143.62% |
| 2021 | NT$94.37 Million | -4.08% |
| 2020 | NT$98.39 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Alar Pharmaceuticals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $367.45 Million USD |
| MoneyControl | $367.45 Million USD |
| MarketWatch | $367.45 Million USD |
| marketcap.company | $367.45 Million USD |
| Reuters | $367.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.